Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.
about
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adultsAddition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthmaIntermittent versus daily inhaled corticosteroids for persistent asthma in children and adultsAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenLong-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsAdd-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive reviewSurvey of adrenal crisis associated with inhaled corticosteroids in the United KingdomCurrent trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone.Decreased cortisol response to insulin induced hypoglycaemia in asthmatics treated with inhaled fluticasone propionate.Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate.Randomized controlled trial of fluticasone in preschool children with intermittent wheeze.
P2860
Q24200804-E8E04BC6-36B0-48C7-9433-63059DE9C440Q24200999-0C0E2A8F-29DB-4392-9437-4C255B674EF6Q24202489-0F6C73B9-4925-4DB2-BC67-4FA6DEFC0DB6Q24234499-C15087FD-70BD-4C29-9614-2507A49550ACQ24235964-40FD0E2A-3611-43EB-A310-9411A0031629Q24240464-99112D01-B557-412D-B28D-96B9294E496FQ24244152-364745D3-A0E4-4407-9343-2BFA62E30A59Q24245719-BABDF17A-E9BB-4774-B7AE-7182761B86DBQ24794527-6D57DBFB-2386-44EE-8FF3-FB15A7D232E4Q34161394-7BB3B6CB-4745-4FE4-970D-B504592CAE29Q34620194-CDD6D6D0-1378-4A83-8DD1-632D4C4FF8C9Q35277394-78C63506-FF15-4F2D-8AE8-5B7E72BB3260Q35627818-0022BE1D-E390-4C2A-9BD4-F13E1DBCB257Q42777551-99BA273B-90F4-45D2-A6AD-1F9BC6F22FB3Q44164456-1189F51F-15BA-435B-9793-1C88DEBB2396
P2860
Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@ast
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@en
type
label
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@ast
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@en
prefLabel
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@ast
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@en
P1433
P1476
Inhaled fluticasone propionate ...... with mild to moderate asthma.
@en
P2093
P304
P356
10.2165/00003495-199957050-00016
P577
1999-05-01T00:00:00Z
P6179
1051499555